Zhao Jia-Guo, Zeng Xian-Tie, Wang Jia, Liu Lin
Department of Orthopaedic Surgery, Tianjin Hospital, Tianjin, China.
Department of Orthopaedic Surgery, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Cangzhou, China.
JAMA. 2017 Dec 26;318(24):2466-2482. doi: 10.1001/jama.2017.19344.
The increased social and economic burdens for osteoporosis-related fractures worldwide make the prevention of such injuries a major public health goal. Previous studies have reached mixed conclusions regarding the association between calcium, vitamin D, or combined calcium and vitamin D supplements and fracture incidence in older adults.
To investigate whether calcium, vitamin D, or combined calcium and vitamin D supplements are associated with a lower fracture incidence in community-dwelling older adults.
The PubMed, Cochrane library, and EMBASE databases were systematically searched from the inception dates to December 24, 2016, using the keywords calcium, vitamin D, and fracture to identify systematic reviews or meta-analyses. The primary randomized clinical trials included in systematic reviews or meta-analyses were identified, and an additional search for recently published randomized trials was performed from July 16, 2012, to July 16, 2017.
Randomized clinical trials comparing calcium, vitamin D, or combined calcium and vitamin D supplements with a placebo or no treatment for fracture incidence in community-dwelling adults older than 50 years.
Two independent reviewers performed the data extraction and assessed study quality. A meta-analysis was performed to calculate risk ratios (RRs), absolute risk differences (ARDs), and 95% CIs using random-effects models.
Hip fracture was defined as the primary outcome. Secondary outcomes were nonvertebral fracture, vertebral fracture, and total fracture.
A total of 33 randomized trials involving 51 145 participants fulfilled the inclusion criteria. There was no significant association of calcium or vitamin D with risk of hip fracture compared with placebo or no treatment (calcium: RR, 1.53 [95% CI, 0.97 to 2.42]; ARD, 0.01 [95% CI, 0.00 to 0.01]; vitamin D: RR, 1.21 [95% CI, 0.99 to 1.47]; ARD, 0.00 [95% CI, -0.00 to 0.01]. There was no significant association of combined calcium and vitamin D with hip fracture compared with placebo or no treatment (RR, 1.09 [95% CI, 0.85 to 1.39]; ARD, 0.00 [95% CI, -0.00 to 0.00]). No significant associations were found between calcium, vitamin D, or combined calcium and vitamin D supplements and the incidence of nonvertebral, vertebral, or total fractures. Subgroup analyses showed that these results were generally consistent regardless of the calcium or vitamin D dose, sex, fracture history, dietary calcium intake, and baseline serum 25-hydroxyvitamin D concentration.
In this meta-analysis of randomized clinical trials, the use of supplements that included calcium, vitamin D, or both compared with placebo or no treatment was not associated with a lower risk of fractures among community-dwelling older adults. These findings do not support the routine use of these supplements in community-dwelling older people.
全球范围内与骨质疏松症相关骨折的社会和经济负担不断增加,使得预防此类损伤成为一项主要的公共卫生目标。先前的研究对于钙、维生素D或钙与维生素D联合补充剂与老年人骨折发生率之间的关联得出了不一致的结论。
探讨钙、维生素D或钙与维生素D联合补充剂是否与社区居住的老年人骨折发生率较低相关。
从创刊日期至2016年12月24日,系统检索PubMed、Cochrane图书馆和EMBASE数据库,使用关键词钙、维生素D和骨折来识别系统评价或荟萃分析。确定系统评价或荟萃分析中纳入的主要随机临床试验,并于2012年7月16日至2017年7月16日额外检索最近发表的随机试验。
比较钙、维生素D或钙与维生素D联合补充剂与安慰剂或不治疗对50岁以上社区居住成年人骨折发生率影响的随机临床试验。
两名独立的评审员进行数据提取并评估研究质量。使用随机效应模型进行荟萃分析以计算风险比(RRs)、绝对风险差异(ARDs)和95%置信区间(CIs)。
将髋部骨折定义为主要结局。次要结局为非椎体骨折、椎体骨折和总骨折。
共有33项涉及51145名参与者的随机试验符合纳入标准。与安慰剂或不治疗相比,钙或维生素D与髋部骨折风险无显著关联(钙:RR,1.53[95%CI,0.97至2.42];ARD,0.01[95%CI,0.00至0.01];维生素D:RR,1.21[95%CI,0.99至1.47];ARD,0.00[95%CI,-0.00至0.01])。与安慰剂或不治疗相比,钙与维生素D联合补充剂与髋部骨折无显著关联(RR,1.09[95%CI,0.85至1.39];ARD,0.00[95%CI,-0.00至0.00])。未发现钙、维生素D或钙与维生素D联合补充剂与非椎体、椎体或总骨折发生率之间存在显著关联。亚组分析表明,无论钙或维生素D剂量、性别、骨折史、饮食钙摄入量和基线血清25-羟基维生素D浓度如何,这些结果总体上是一致的。
在这项随机临床试验的荟萃分析中,与安慰剂或不治疗相比,使用包含钙、维生素D或两者的补充剂与社区居住老年人骨折风险较低无关。这些发现不支持在社区居住的老年人中常规使用这些补充剂。